RT Journal Article SR Electronic T1 Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5455 OP 5461 VO 36 IS 10 A1 KOH, HYEON KANG A1 CHIE, EUI KYU A1 KIM, KYUBO A1 JANG, JIN-YOUNG A1 KIM, SUN WHE A1 OH, DO-YOUN A1 IM, SEOCK-AH A1 BANG, YUNG-JUE A1 HA, SUNG W. YR 2016 UL http://ar.iiarjournals.org/content/36/10/5455.abstract AB Aim: To analyze the outcomes of patients with unresectable pancreatic cancer after chemoradiotherapy (CCRT), focusing on sequencing strategy. Patients and Methods: Data of 144 patients treated from January 1989 to December 2013 were retrospectively analyzed. Patients were divided into the scheduled group (N=27), salvage group (N=37) and upfront group (N=80) per CCRT and chemotherapy sequence. Results: With a median follow-up of 10.4 months (range=1.4-164.2), median overall survival (OS) was 13.5 months. Patients in the upfront group had inferior performance status and received a lower radiation dose (p=0.007 and p<0.001, respectively). Higher radiation dose (≥45 Gy) was the sole prognosticator related with improved survival in multivariate (p=0.001) analysis, whereas treatment sequence was not a significant prognostic factor (p=0.409). Conclusion: No difference was found among tested sequencing strategies that were all well-tolerated, despite skewed distribution for performance and radiation dose. An upfront approach may be a viable option for patients with limited performance to undergo more active systemic chemotherapy.